Repeat radiofrequency thermocoagulation for multiple sclerosis-associated versus idiopathic trigeminal neuralgia: a comparison of long-term pain control.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 42247695.
- Also identified by DOI 10.3171/2026.1.JNS251957.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Radiofrequency thermocoagulation (RFT) of the gasserian ganglion provides rapid pain relief in trigeminal neuralgia (TN) and is minimally invasive. In multiple sclerosis (MS)-associated TN (MS-TN), recurrence may be more frequent than in idiopathic/classic TN (Id-TN), possibly due to demyelinating pathology. This study compared RFT outcomes between these etiologies. The authors conducted a STROBE-compliant, single-center retrospective cohort study that screened 636 patients with TN treated between March 2012 and September 2021. Structured telephone interviews were completed in 350 patients, including the 5-level EQ-5D (EQ-5D-5L) for health-related quality of life (HRQOL). Of these patients, 182 received RFT as their first invasive treatment. The primary endpoint was the pain-free interval (PFI), defined as the time to recurrence (Barrow Neurological Institute Pain Intensity Scale score ≥ II or medication restart), analyzed using Kaplan-Meier curves and Cox proportional hazards regression models. Secondary outcomes included repeat interventions, permanent sensory deficits, and HRQOL. Of 182 eligible participants, 77 had MS-TN and 105 had Id-TN. Patients with MS-TN were younger (mean age 55.8 [SD 10.6] vs 70.5 [SD 8.6] years, p < 0.001). The median PFI was 33.9 (95% CI 15.5-52.3) months for MS-TN versus 87.0 (95% CI 43.1-130.9) months for Id-TN (p = 0.0493, log-rank test). The mean overall follow-up duration was 68.4 months. Despite earlier recurrence, repeat interventions achieved comparable adequate pain control at the last follow-up (68.8% in MS-TN vs 77.1% in Id-TN, p = 0.139). EQ-5D-5L scores improved significantly and converged at follow-up (p = 0.085). After the first RFT, pain control was shorter in MS-TN than in Id-TN. However, retreatment effectively restored long-term pain control and HRQOL, supporting the role of RFT in managing MS-TN. Regular follow-up is recommended to facilitate timely intervention.